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Background
Splenic diffuse red pulp small B-cell lymphoma is an uncommon B-cell lymphoma, now recog-
nized as a provisional entity in the 2008 update of the WHO Classification. Additional work is
required to review this entity and establish its diagnostic features.
Design and Methods
We have retrospectively analyzed the disease features in a highly selected series of 17 patients
diagnosed as splenic diffuse red pulp small B-cell lymphoma.
Results
The median age was 65.5 years (range 40-79 years) and there was a predominance of males
(male/female ratio: 2.4). Clinical manifestations were mainly derived from splenomegaly.
Splenectomy was the front-line treatment in 11 symptomatic patients; the remaining 6
received chemotherapy initially followed by splenectomy. After a mean follow-up of 72
months, the five-year overall survival was 93%. 
All cases showed a purely diffuse pattern of splenic infiltration by monomorphous small cells
with small round nuclei and pale cytoplasm. All bone marrow biopsies showed tumoral infil-
tration, with intrasinusoidal infiltration. Peripheral blood cells were small to medium-sized,
with clumped chromatin and round nuclear outline and villous cytoplasm. 
Neoplastic cells had a CD20+, CD23–, bcl6–, Annexin A1- phenotype, with frequent expression
of DBA44+ (15/17) and IgG (10/15). FCM data had a B-cell phenotype (CD19+, CD20+, CD22+)
with FMC7 (10/11) and CD11c (5/8) expression. Clonal IgH rearrangement studies in 4 cases
showed IgVH mutations in all cases, without VH1.2 usage.
Conclusions
Our data suggest that splenic diffuse red pulp small B-cell lymphoma is a distinct entity with
morphological and immunophenotypical features that differ from those of other splenic lym-
phomas.
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Introduction
Splenic diffuse red pulp small B-cell lymphoma
(SDRPSBCL) is an uncommon B-cell lymphoma with a
diffuse pattern of involvement of the splenic red pulp by
small monomorphous B lymphocytes now recognized as
a provisional entity in the 2008 update of the WHO
Classification,1 and initially identified as a potential vari-
ant of splenic marginal zone lymphoma (SMZL) with a
diffuse pattern of splenic involvement.2 SDRPSBCL cases
are characterized by a leukemic course, with relatively
low lymphocytosis, massive splenomegaly and infre-
quent B symptoms. Most cases are diagnosed at clinical
stage IV, with spleen, bone marrow (BM) and peripheral
blood (PB) involvement.1 Criteria for SDRPSBCL recogni-
tion have mainly been based on spleen histology. 
The description of the features of this lymphoprolifer-
ative disorder requires further investigation to establish
whether it is a separate disease with characteristic clini-
cal and diagnostic features. Information about histology
and immunophenotype, clinical presentation and
response to therapy is very limited and its possible over-
lap with typical SMZL, hairy cell leukemia-variant (HCL-
v) and other B-cell disorders with splenomegaly is uncer-
tain.1,3 Indeed, patients with this diagnosis have fre-
quently been described by alternative terms, such as dif-
fuse variant of splenic marginal zone lymphoma, or
splenic red pulp lymphoma with numerous basophilic
villous lymphocytes.2-4 The lack of information precludes
the establishment of appropriate staging or therapeutic
recommendations. 
We have collected a series of cases over recent years
that could fit this diagnosis. Here we describe the disease
features in a highly selected group of 17 cases, with clin-
ical follow-up and a comprehensive histopathology,
which may constitute a representative series of cases
with this morphology and be useful for a better under-
standing of the entity. Our data suggest that SDRPSBCL
probably constitutes a distinct entity with different mor-
phological and immunophenotypical characteristics.
Design and Methods
Patient selection and clinical data
Cases were selected from the routine files (1995-2008) of the
Spanish National Cancer Research Centre, Madrid, and
Hospital Virgen de la Salud; Toledo, Spain (Table 1). Two of
these cases have been previously reported.2
The selection of cases was based on spleen histology show-
ing features of splenic diffuse red pulp small B-cell lymphoma
as described in the 2008 WHO Lymphoma Classification
update.1 Cell morphology, immunohistochemical analysis and
clinical data were used to exclude entities with similar histolog-
ical features in the spleen, such as chronic lymphocytic
leukemia (CLL), hairy cell leukemia (HCL), lymphoplasmacytic
lymphoma (LPL) and prolymphocytic lymphoma (PLL).
Research was performed under the supervision of the
Institutional Review Board of the Hospital Virgen de la Salud,
Toledo, Spain.
The following clinical data were obtained from the referring
clinicians: age, clinical manifestations at diagnosis, stage, treat-
ment and outcome. Overall survival (OS) was defined as the
time from the date of diagnosis to the date of death or last fol-
low-up. Student’s t-test and χ2 tests of association were used to
compare clinical, pathological, and molecular characteristics.
Actuarial survival was analyzed by the Kaplan-Meier method,
and the curves were compared by the log-rank test. All analyses
were carried out with SPSS v15 (SPSS, Chicago, IL, USA).
Morphology and immunohistochemistry
Bone marrow (14 cases) and spleen (17 cases) tissues were
processed in the conventional manner for histopathological stud-
ies by paraffin embedding and hematoxylin and eosin staining.
May-Grumwald-Giemsa-stained peripheral blood smears were
used for diagnosis. Subtle changes of the protocols for morpholog-
ical examination were observed among different institutions.
Immunohistochemical analysis was performed on formalin-
fixed, paraffin-embedded tissue. Sections were immunostained
using the EnVision method (DAKO, Glostrup, Denmark), with a
heat-induced antigen-retrieval step. Sections were immersed in
boiling 10 M sodium citrate at pH 6.5 for 2 min in a pressure cook-
er. The antibody panel used included CD20, CD3, bcl2, bcl6,
CD23, IgD, CD38, Ki67, kappa and lambda (Dako), CD10, p53,
CD5 (Novocastra, Newcastle, UK), cyclin D1 (Lab Vision, Neo
Markers), Annexin A1 (BD Biosciences). Flow cytometry was car-
ried out on the circulating neoplastic lymphocytes from 14 cases
on a CD19+ gate with a variety of monoclonal antibodies (McAb)
against B cells and with “hairy cell-associated” markers (Table 2).
A case was considered positive when more than 30% of the neo-
plastic cells stained with the McAb.
FISH for bcl2, bcl1, del 7q, 17p (TP53)
FISH was performed on paraffin-embedded samples as
described by Ferreira et al.5 Briefly, hybridizations were carried out
overnight at 37°C after deparaffinization of 4 μm thick sections of
tissue, target retrieval by pressure cooking with 1 mM EDTA for
10 min, and pepsin digestion (4 mg/mL at 37°C for 60 min). The
probes used were the LSI IGH/BCL2Dual Fusion Color Probe, LSI
BCL6 Dual Color, Break Apart Rearrangement Probe, centromeric
probe for chromosome 7 and TP53 (Vysis R, Abbott Park, IL,
USA). For 7q deletion we selected seven BAC clones from the
BACPAC Resource Center at the Children's Hospital Oakland
Research, CA, USA: clones RP11-10I12, RP11-138A9 covered the
7q32.3 region (genomic bp: 130141293-130377509) and clones
RP11-154N21, RP11-597L6, RP11-166D01, RP11-706J21, RP11-
140I14 covered the 7q33 region (genomic bp:134704640-
135055570).
IgVH somatic mutations assay
The study of IgVH included DNA extracted from paraffin-
embedded tissue specimens. Rearranged IgVH genes were ampli-
fied and sequenced as previously described.6 Cases were consid-
ered mutated when they exhibited less than 98% homology with
the closest germ line VH genes. IgVH sequences were submitted to
IgBLAST and IMGT analysis to obtain VH family usage and muta-
tion information.
Results
Clinical features
The clinical features are summarized in Tables 1 and 2.
The median age was 65.5 years (range 40-79 years); 12/17
(70.5%) were males, giving a male/female ratio of 2.4.
Clinical manifestations, such as abdominal pain and/or
hypersplenism (cytopenias), were mainly derived from
splenomegaly and bone marrow infiltration. B symptoms
were recorded in 6/17 (35.3%) cases. In 3 patients the dis-
ease was diagnosed as a result of infections or lymphocy-
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tosis in routine analysis, or incidentally. All patients were
fully active, with a performance status (PS/ECOG) of 0 or
1. One patient had a previous history of rheumatoid
arthritis. No other previous autoimmune conditions were
recorded in the remaining patients. Serology for HCV or
HIV infection was negative in all cases.
All patients had Ann-Arbor stage IV disease, with
involvement of the spleen and peripheral blood in all but
one case, which had bone marrow involvement. Bone
marrow infiltration was present in 14/14 (100%) patients
for whom this information was available. Splenic hilar
lymph nodes were involved in 3/17 (18%) cases, and liver
was involved in 3/17 (18%) cases. CT scans showed
abdominal and mediastinal lymphadenopathy in only one
case. Two cases showed cutaneous infiltration at diagno-
sis manifested as erythematous and pruritic papules. The
skin biopsy showed dermal lymphoid infiltrates, arranged
around the appendages and blood vessels.
Peripheral blood findings were as follows: leukocyte
counts ranged from 3.5 to 86¥109/L (median 11¥109/L),
lymphocyte counts from 1 to 28¥109/L (median 5.4¥109/L),
hemoglobin values ranged from 7.8 to 15.5 g/dL (median
12.2 g/dL) and platelet numbers ranged from 13 to
1,572¥109/L (median 112¥109/L). Eight out of 16 (50%)
patients presented with lymphocytosis (> 5¥109/L).
Anemia (< 10 g/dL) was observed in 2 out of 16 (12.5%)
patients and thrombocytopenia (platelets < 100¥109/L) in
5 out of 16 (31.2%) patients, 2 of whom (12.5%) with
leukocytopenia (leukocytes < 4¥109/L). Only one case (N.
13) had a serum monoclonal paraprotein IgM Lambda.
Histological, cytological, immunophenotypical 
and molecular features
Spleen weight ranged from 518 to 5,500 g (median 2,046
g), with a homogeneously brown-red cut surface, without
nodularity. All cases had a purely diffuse pattern of infil-
tration, replacing both the white and red pulp in the
majority; some residual lymphoid follicles were present in
8 cases. Red pulp involvement was seen in both the cords
and sinusoids, with some cases showing stuffed cords,
filled up by the tumoral cells. Sinusoidal dilatation form-
ing pseudo-blood lakes were seen in 5 cases (Figures 1-3).
Neither follicular replacement and biphasic cytology, nor
marginal zone infiltration was seen; pseudofollicles (pro-
liferation centers) were not identified.
Neoplastic cells were remarkably homogeneous in the
tissue sections, being characterized by a small round
nucleus with clumped chromatin and a pale or lightly
eosinophilic cytoplasm with plasmocytoid features, but
lacking cytoplasmic basophilia. Scattered large cells were
present. 
All bone marrow biopsies evaluated showed tumoral
infiltration, which was always partial, with an interstitial
or micronodular pattern (4 cases). When present, the nod-
ules were intertrabecular. All cases showed some degree
of sinusoidal infiltration, and in 5 cases the tumor was
only demonstrated after CD20 staining within bone mar-
row sinusoids.
Immunohistochemistry in the spleen sections (Figure 4)
showed the lymphoid cells to have a CD20+, CD23–, bcl6–,
Annexin A1- phenotype (Table 3). Expression of other
markers was as follows: DBA44 + in 15 out of 17 (88.2%),
p53 + in 5 out of 17 (29.4%), CD5 + in 1 out of 16 (6.25%),
CD38 + in 1 out of 12 (8.3%), IgG + in 10 out of 15
(66.7%), IgD + in 4 out of 15 (26.6%) and kappa in 2 out
of 6 (33.3%) cases and lambda 4 out of 6 (66.7%) cases
analyzable for light-chain expression. CyclinD1 was neg-
ative in all but one case, which had moderate expression
that was weaker than observed in the macrophages and
endothelial cells. In this case the t(11; 14) by FISH was
negative. Bcl2 was weakly positive in all cases, with some
rare Bcl2-negative germinal centers highlighted with this
marker. Proliferation index was low (ki-67 < 10%) in 16
out of 17 cases; only scattered and dispersed tumoral ki-
67-positive cells were observed. Case 7 had a slightly
higher proliferation index (ki-67 > 10%). An annular or
target pattern, a finding typical of SMZL, was not
observed in any case in this series. Residual CD3+ T cells
were present in peritrabecular locations.
The blood-circulating neoplastic cells were small- to
medium-sized lymphoid cells, with clumped chromatin
and round nuclear outline, with villous cytoplasm, in 11
out of 13 (84.6%) cases. Occasionally, a few large cells
G. Kanellis et al.
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Table 1. Clinical features of the series.
Case Age/ Disease Ecog Stage Treatment Response Actual
Sex location status
(months)
1 74/F Spleen, BM 0 IV Splenectomy CR DOC (86) 
2* 73/M Spleen, BM, 1 IV Splenectomy + CT SD AWD (149)
PB, liver, skin 
3 62/M Spleen, BM, ND IV CT + splenectomy PR DOC (65) 
PB (at 8 months)  
4 71/F Spleen, BM, ND IV-A Splenectomy CR DOC (105) 
PB 
5 71/M Spleen, BM, 1 IV-A Splenectomy SD DOC (84) 
PB, liver
6 69/M Spleen, BM, 0 IV Splenectomy  PR  AD (124) 
PB (at 80 months) 
7 66/M Spleen, BM, 0 IV-B Splenectomy + PR DOD (25) 
PB CT + Rt  
8 58/F Spleen, BM, 0 IV-A Splenectomy N/A AWD  (64) 
PB (at 24 months) 
9 40/M Spleen, BM, 1 IV-B Splenectomy CR AWD  (35) 
PB 
10 70/F Spleen, BM, 1 IV Splenectomy +IF N/A AD (203)  
PB 
11* 72/M Spleen, BM, 1 IV Splenectomy + CT Prog DOD (100)
PB, liver, skin
12 60/F Spleen, BM, 0 IV-B Splenectomy SD AWD (29)   
PB  
13 48/M Spleen, PB  1 IV-B Splenectomy CR AWD (31) 
14 60/M Spleen, PB 0 IV-A  Splenectomy PR AD (43)  
(at 30 months) 
15 79/M Spleen, PB  1 IV-B  Splenectomy CR AWD (9)
+ CT  
16 70/M Spleen, BM, 1 IV-A Splenectomy Prog AD (168)
PB  (at 168 months)  
17 64/M Spleen, BM, 1 IV-B  CT + Splenectomy  Prog AD (40)
PB (at 36 months) 
F: female, M: male; BM: bone marrow; PB: peripheral blood, LN:  lymph node; CT: chemotherapy, IF: inter-
feron, Rt: radiotherapy; DOC: dead of others causes, AD: alive  with disease, AWD: alive without disease,
DOD: dead of disease; CR: complete remission, PR: partial  remission, SD: stable disease, Prog: progres-
sion  *Cases previously described.2
with nucleoli were observed but this was not the predom-
inant population. 
FCM data were available from blood of 14 cases, show-
ing a B-cell phenotype (CD19+, CD20+, CD22+) with
FMC7 expression in 10 out of 11 (91%) cases. CD11c was
positive in 6 out of 9 (67%) cases, CD25 in one  out of 10
(10%), CD103 in one out of 6 (16.7%) and CD123 in one
out of 2 (50%) cases. None had a chronic lymphocytic
leukemia immunophenotype (coexpression of CD5+ and
CD23+), but 4 out of 11 (36.4%) cases were CD5-positive.
Three out of 6 (50%) cases showed kappa light-chain
restriction and the remaining 3 had a lambda light chain
(Table 2). 
FISH analysis of t(11;14) and t(14;18) gave negative
results in all cases and deletion 7q was detected in one out
of 13 (7%) cases investigated. LOH by FISH of TP53 was
present in 2 out of 13 (15.3%) cases, one of whom showed
disease progression and finally died of the disease.
Splenic diffuse red pulp small B-cell lymphoma
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Table 2. Peripheral blood and flow cytometry data.
Case* Lymphocytes Platelets Hemoglobin Flow cytometry
x109/L x109/L (g/dL) CD5 CD10 CD11c CD19 CD20 CD23 CD25 CD38 CD43 Light
chains
2** 3.12 82 13.9 NEG NA NEG NA POS NEG NEG NA NA NA
4 11.8 340 15.8 NA NEG POS POS POS NA NEG NEG NA κ+/λ-
6 9.03 111 11.5 POS NEG NEG POS POS NEG NEG NA NA κ+/λ-
7 14 13 8.8 NEG NA NA POS POS NEG NEG NA NA NA
8 3.65 140 12.7 NA NA POS POS POS NEG NEG NA NA NA
9 2.65 163 7.8 NEG NEG NA POS POS NA NA NA NA NA
10 17.48 106 12.4 NEG NEG NA POS POS NEG NEG NA NA NA
11** 1.52 64 13.1 NA NA NEG NA POS NEG NEG NA NEG NA
12 2.98 190 12.7 POS NEG NA NA NA NEG NA NA NEG κ+/λ-
13 6.3 1090 11.2 POS NEG POS NA POS NEG NA POS NEG NA
14 28 143 14.6 POS NEG NA POS NA NEG NA NA NA κ+/λ-
15 26.1 191 15.5 NEG NEG POS POS POS NEG POS NEG NA NA
16 NA NA NA NEG NA POS POS POS NEG NEG NA NA κ+/λ-
17 1.4 142 14.1 NEG NA POS POS POS NEG NEG NA NA κ+/λ-
NA: Not available, *Cases 1,3,and 5 had no FCM data and are not included in the table.  **Cases previously described.2
Figure 1. (A) Splenic histology, with
diffuse infiltration erasing follicles,
occupying both cords and sinusoids.
(B) Wilder staining highlighting sinu-
soidal dilatation forming pseudo-
blood lakes. (C and D) Neoplastic
cells have monomorphous cytology,
round nuclei with clumped chro-
matin and pale cytoplasm.
We amplified and sequenced 5 clonal IgH rearrange-
ments from 4 cases. All of them were mutated and case 2
had two amplified clonal rearrangements (no clonality
study was performed on infiltrated skin). The VH families
used were different in each case: VH1.69, VH6.1, VH3.30,
VH3.74 and VH5 (Table 3).
Treatment and follow-up
Splenectomy was the front-line treatment in 11 out of
17 (64.7%) symptomatic patients; the remaining 6 out of
17 (35.2%) received initially chemotherapy followed by
splenectomy at eight, 24, 30, 36, 80 and 168 months from
diagnosis. Eleven patients out of 17 (64.7%) were alive at
the last follow-up; 6 out of 11 (54.5%) of them were with-
out disease activity and the other 5 out of 11 (45.5%) had
active disease. Two patients (11.8%) died due to disease
progression and 4 (23.5%) died from other causes: 2 with
acute myeloblastic leukemia and 2 from infection. Two of
the latter cases died when in remission from their lym-
phoma. Four patients showed clinical progression after
splenectomy with, skin (# 2 and # 11), liver (# 2, # 5 and #
11), testicular and systemic involvement (# 7). One of
these patients was diagnosed with large B-cell lymphoma
transformation in a lymph node biopsy. At a mean follow-
up of 72 months (range 9-203), the five-year overall sur-
vival was 93% (Figure 5). The comparison of the periph-
eral blood parameters, hemoglobin, leukocyte count, lym-
phocyte count, platelets and lactate dehydrogenase, with
overall survival revealed that hemoglobin values less than
10 g/dL was the only parameter significantly associated
with poor survival (P<0.05).
Discussion
Although splenic marginal zone lymphoma (SMZL) is
the most frequent splenomegalic small B-cell lymphoma,
there is a subset of cases whose clinical presentation mim-
ics SMZL but whose cells have a different morphology
and immunophenotype. We have retrospectively ana-
lyzed the disease features of a series of patients who, on
histological grounds, correspond to the provisional entity
recognized in the new WHO classification as splenic dif-
fuse red pulp small B-cell lymphoma (SDRPSBCL), in an
attempt to provide a more detailed description of the fea-
tures of this entity. The frequency of SDRPSBCL is diffi-
cult to estimate, but in the series of consultation cases of
the Spanish National Cancer Research Centre, it repre-
sents 9% of the splenic B-cell lymphomas seen in a 12-
year period. Nevertheless, the frequency of the disease in
the general population cannot be established here; its
determination would require population-based studies.
The spectrum of cases described here probably represents
those in which splenectomy was considered necessary
and in which the pathologists decided to discuss the case
due to its unusual infiltration pattern. Most probably,
other less aggressive cases which do not require splenec-
tomy also exist; such as the majority of the cases reported
by Traverse-Glehen and co-workers.4
This series highlights some potentially useful clinical,
morphological and immunophenotypical features of this
disease. In most of these cases the clinical features at pres-
entation suggested a diagnosis of SMZL/SLVL, diffuse
variant of SMZL or HCL-variant.3,7-11 Nevertheless, it
seems that there are some clear differences among these
G. Kanellis et al.
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Table 3. Immunohistochemical and molecular features. 
Cases CD20 CD23 CD5 DBA44 Annexin A1 CD38 Cyclin D1 p53 SIg cIg FISH7q FISH P53 IGHV** SHM %**
1 POS NEG NEG POS NEG ND NEG POS ND − NEG NEG NR −
2*** POS NEG NEG NEG NEG NEG NEG POS ND − NEG NEG VH1.69; VH 6.1 93,8
97,5
3 POS NEG NEG POS NEG NEG NEG NEG G − ND ND ND −
4 POS NEG NEG POS NEG NEG NEG POS G − NEG NEG ND −
5 POS NEG NEG POS NEG ND NEG NEG G − NEG NEG NR −
6 POS NEG NEG POS NEG NEG NEG NEG D − POS NEG NR −
7 POS NEG NEG POS NEG POS NEG POS D − NEG POS VH3.30 91,28
8 POS NEG NEG POS NEG ND NEG NEG G − NEG NEG VH3.74 97,5
9 POS NEG NEG POS NEG NEG NEG NEG G − NEG NEG ND −
10 POS NEG NEG POS NEG NEG NEG NEG G − NEG NEG NR −
11*** POS NEG NEG NEG NEG NEG NEG POS ND − NV ND ND −
12 POS NEG NEG POS NEG ND NEG NEG G − ND ND ND −
13 POS NEG POS POS NEG NEG NEG NEG G − NEG NEG NR −
14 POS NEG NEG POS NEG NEG NEG NEG G − NV ND NR −
15 POS NEG NEG POS NEG NEG NEG NEG G − NEG NEG VH5.a 82,2
16 POS NEG NEG POS NEG ND POS* NEG D − NEG NEG ND −
17 POS NEG NEG POS NEG NEG NEG NEG D − NEG POS ND −
SHM: somatic hypermutations, IGHV: Immunoglobulin Heavy chain Variable gene region, POS: positive, NEG: negative; NR: no results; ND: not determined. * Weak scattered expres-
sion. **IGHV indicates the VH gene family usage.  The SHM% indicates the percentage of homology with germline VH sequences.  Below 98% the sequence is considered mutated
***Cases previously described.
2
entities. Thus, there is a predominance of males
(male/female ratio: 2.4) in SDRPSBCL, in contrast with the
even distribution or slight female predominance usually
seen in SMZL.12 The degree of lymphocytosis was similar
to that of typical SMZL but significantly lower than in
HCL-v where median lymphocyte counts are 35¥109/L.
Additionally, SDRPSBCL cases in this series appear to pur-
sue a relatively favorable clinical course, with 93% of
patients alive after 65 months of follow-up, which com-
pares favorably with the 60% survival in SMZL cases.12
Not surprisingly, considering the low aggressivity of this
neoplasm and the long follow-up of this series, some of
the patients developed second tumors, this being a signif-
icant cause of morbidity and mortality. Nevertheless, a
caveat must be applied since, as all patients were diag-
nosed after splenectomy, this series could have been sub-
ject to selection bias. A more favorable outcome would be
expected if cases at early stages of the disease, when
splenectomy is not required, were included. 
As in other B-cell neoplasms, the diagnosis of SDRPSB-
CL was based here on a constellation of features, spleen
histology being essential for such a diagnosis in this series.
Diagnosis after splenectomy is thus facilitated by the char-
acteristic diffuse infiltration of the splenic red pulp, which
contrasts with the usual pattern of infiltration of SMZL,
where neoplastic cells in different microenvironments
undergo morphological changes (marginal zone and plas-
mocytoid differentiation being an example), while in
SDRPSBCL neoplastic cells are very monomorphous, irre-
spective of the area of the spleen involved. Thus, diffuse
monomorphic splenic histology is the hallmark of this
lymphoma and is clearly different from typical SMZL,
which is characterized by a distinct micronodular pattern
with white pulp replacement and marginal zone differen-
tiation. By contrast, the pattern in SDRPSBCL is very sim-
ilar to that seen in hairy cell leukemia (HCL). The histol-
ogy of the spleen in HCL-v has not been described in suf-
ficient detail, but the features of HCL usually overlap with
those of SDRPSBCL. However, splenic histology is not
always available and a combination of other features, such
as bone marrow histology, cell morphology and
immunophenotype, can be helpful for recognizing this
disease. Intrasinusoidal bone marrow infiltration frequent-
ly occurs in this disorder but is also common in other B-
cell lymphomas with splenomegaly, particularly SMZL
and HCL.13 The immunophenotype of SDRPSBCL is
somewhat different from that of typical SMZL as the cells
in SDRPSBCL strongly express DBA44 whilst only a frac-
tion of cells are DBA44+ with variable intensity in SMZL.
Furthermore, SDRPSBCL cells are frequently IgG-positive
and appear to express p53 more frequently than expected
in SMZL (29.4% vs. 14% for SMZL). HCL can be distin-
guished by the frequent severe pancytopenia, bone mar-
row fibrosis and immunophenotypic profile with expres-
sion of Annexin-A1, CD25, CD103 and CD123 markers,
which are usually negative in SDRPSBCL. The lack of
staining for Annexin A1 is especially important in these
cases, since it is a highly specific HCL marker that can be
reliably investigated in paraffin-embedded material.14
SDRPSBCL and HCL-v share some features, such as the
frequent use of IgG and DBA44 expression, and cutaneous
infiltration is present in a minority of cases.11,15 However,
unlike SDRPSBCL, HCL-v affects older patients, presents
with significantly higher lymphocyte counts and the cir-
culating cells have a distinct morphology with a promi-
nent single nucleolus that mimics prolymphocytes. In
addition, the cells frequently express CD103 and the out-
come seems less favorable, with a median survival of nine
years.1 The frequency of TP53 deletions is lower in
SDRPSBCL than in HCL-v.16 It is nevertheless possible that
some cases have features shared by both these entities.
Splenic diffuse red pulp small B-cell lymphoma
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Figure 2. Circulating blood neoplastic lymphoid cells, of small to
medium size with condensed chromatin, round or slightly cleaved
nuclear outline and villous cytoplasm.
Figure 3. Bone
marrow intersti-
t ia l/ in t ras inu -
soidal infiltration,
barely recogniza-
ble in some
cases by (A) H &
E and (B) CD20
staining.
This is an area that warrants further study. 
A diagnosis of lymphoplasmacytic lymphoma (LPL)
could be considered because of the pseudoplasmacytic
features; indeed, it was frequently proposed by the sub-
mitting pathologists. However, a monoclonal component
and CD38 expression were only occasionally present, and
no single case showed the polymorphous cytological com-
position in the spleen of small B-lymphoid cells and neo-
plastic plasma cells seen in LPL. Additionally, immunos-
taining did not demonstrate the strong cytoplasmic
immunoglobulin presence that characterizes  lymphoplas-
macytic lymphoma.
Other cytogenetic and IgVH mutational data can also be
useful for recognizing this disease. For instance, deletion
of 7q, a relatively recurrent chromosome abnormality in
SMZL,17 was found in only one out of 13 cases (7.6%) of
SDRPSBCL, a notably lower frequency than in SMZL, in
which it occurs in around 45% of cases. Although initial-
ly proposed to be a specific marker for SMZL,17 7q losses
have been found in a small proportion of other B-cell lym-
phoma cases using CGH arrays.5 In 5 cases of this series,
we were able to assess the mutational status of the clonal
IgH rearrangements. All cases were mutated; none of the
G. Kanellis et al.
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Figure 4. Illustrations of the characteristic immunophenotype by IHC: (A) CD20. (B) CD3. (C) DBA44. (D) IgD. (E) BCL2. (F) p53. (G) IgG. (H)
IgD. (I) MIB1.
Figure 5. Overall survival probability for the series.
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cases showed usage of the VH1.2 gene that is characteris-
tic of SMZL.18
The cases described here seem to overlap partially with
the series of 37 cases reported by Traverse-Glehen and co-
workers, denominated splenic red pulp lymphoma with
numerous basophilic villous lymphocytes.4 These patients
were older men, with moderate lymphocytosis and
splenomegaly without pancytopenia. Neoplastic cells
showed an immunophenotype IgM + D, IgM + G, IgM or
IgG, as well as CD76 (DBA44) and CD11c, frequently
CD103+, and rarely CD123+. Spleen histology was only
available in some of these cases and described as “atrophic
white pulp with a monomorphic diffuse lymphoma infil-
tration in a congested red pulp”. Bone marrow infiltration
was described as interstitial and intrasinusoidal without
extensive fibrosis. Most cases (79%) were IgVH-mutated,
with an overrepresentation of VH3 and VH4 gene families.
In this series, splenic lymphoma with basophilic villous
cells also exhibited a significant difference in time to pro-
gression compared with SMZL cases.4 The two studies
cannot be compared directly since in our study the cases
were included on the basis of spleen morphology and IHC,
while those in the Traverse-Glehen study were mainly
diagnosed on the basis of peripheral blood morphology
and FCM.4 In this series of cases initially studied in differ-
ent clinical centers, we had some problems applying the
cytological criteria used by Traverse-Glehen and co-work-
ers. Review of consecutive case series in the future will
probably allow the features of SDRPSBCL to be refined.
In summary, SDRPSBCL is emerging as a distinct dis-
ease with some specific features that allow it to be distin-
guished from SMZL and other splenic lymphomas, espe-
cially the diffuse splenic involvement and the IgG and
DBA44 frequent expression. More work is needed to
establish more precise diagnostic markers that would
allow this lymphoma to be identified on the basis of
peripheral blood and bone marrow features, without
requiring information about spleen histology.
Identification of specific molecular markers should also
facilitate disease-specific therapeutic strategies.
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